EA201591773A1 - Макроциклические ингибиторы rip2-киназы - Google Patents
Макроциклические ингибиторы rip2-киназыInfo
- Publication number
- EA201591773A1 EA201591773A1 EA201591773A EA201591773A EA201591773A1 EA 201591773 A1 EA201591773 A1 EA 201591773A1 EA 201591773 A EA201591773 A EA 201591773A EA 201591773 A EA201591773 A EA 201591773A EA 201591773 A1 EA201591773 A1 EA 201591773A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- rip2
- kinase
- inhibitors
- macro cyclic
- cyclic inhibitors
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 101001109137 Homo sapiens Receptor-interacting serine/threonine-protein kinase 2 Proteins 0.000 abstract 2
- 102100022502 Receptor-interacting serine/threonine-protein kinase 2 Human genes 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 101000733257 Homo sapiens Rho guanine nucleotide exchange factor 28 Proteins 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 239000000032 diagnostic agent Substances 0.000 abstract 1
- 229940039227 diagnostic agent Drugs 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940043355 kinase inhibitor Drugs 0.000 abstract 1
- 150000002678 macrocyclic compounds Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1304714.7A GB201304714D0 (en) | 2013-03-15 | 2013-03-15 | Macrocyclic RIP2 Kinase inhibitors |
| EP2013066732 | 2013-03-15 | ||
| PCT/EP2014/055139 WO2014140299A1 (en) | 2013-03-15 | 2014-03-14 | Macrocyclic rip2 kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201591773A1 true EA201591773A1 (ru) | 2016-01-29 |
Family
ID=50342296
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201591773A EA201591773A1 (ru) | 2013-03-15 | 2014-03-14 | Макроциклические ингибиторы rip2-киназы |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20160024114A1 (enExample) |
| JP (1) | JP2016510796A (enExample) |
| KR (1) | KR20150133765A (enExample) |
| CN (1) | CN105228625A (enExample) |
| AU (1) | AU2014230111A1 (enExample) |
| BR (1) | BR112015022982A2 (enExample) |
| CA (1) | CA2906257A1 (enExample) |
| EA (1) | EA201591773A1 (enExample) |
| HK (1) | HK1218263A1 (enExample) |
| IL (1) | IL241250A0 (enExample) |
| MX (1) | MX2015012526A (enExample) |
| SG (1) | SG11201507594YA (enExample) |
| WO (1) | WO2014140299A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016146651A1 (en) * | 2015-03-16 | 2016-09-22 | Oncodesign Sa | Macrocyclic activin-like receptor kinase inhibitors |
| US11166967B2 (en) | 2016-05-19 | 2021-11-09 | Universiteit Antwerpen | Bis(acetamidophenyl) guanidinophenylethylphosphonates for use in the prevention and/or treatment of PAR-related diseases |
| AU2017302019A1 (en) * | 2016-07-28 | 2019-02-07 | Turning Point Therapeutics, Inc. | Macrocycle kinase inhibitors |
| KR102719387B1 (ko) * | 2017-01-26 | 2024-10-21 | 한미약품 주식회사 | 이미다조피리다진 화합물 |
| CN110386944B (zh) * | 2018-04-16 | 2021-10-29 | 深圳市塔吉瑞生物医药有限公司 | 用于抑制蛋白激酶活性的二(杂)芳基大环化合物 |
| RS66346B1 (sr) | 2018-10-22 | 2025-01-31 | Alumis Inc | Inhibitori tyk2 i njihova upotreba |
| CA3168814A1 (en) * | 2020-01-31 | 2021-08-05 | Oncodesign S.A. | Macrocyclic rip2-kinase inhibitors |
| IL301385A (en) | 2020-09-16 | 2023-05-01 | Alumis Inc | TYK2 inhibitors and their use |
| AU2023339247A1 (en) * | 2022-09-07 | 2025-03-27 | Suzhou Langrui Biopharmaceutical Co., Ltd. | Macrocyclic imidazo[1,2-b]pyridazine derivative, preparation method therefor, and use thereof |
| WO2025212514A2 (en) * | 2024-04-02 | 2025-10-09 | Interline Therapeutics, Inc. | Methods of treating inflammatory diseases |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPQ120999A0 (en) * | 1999-06-25 | 1999-07-22 | Industrial Automation Services Pty Ltd | Vibration suppressing piston |
| JP2004089182A (ja) * | 2002-06-24 | 2004-03-25 | Takeda Chem Ind Ltd | がんの予防・治療剤 |
| TWI547494B (zh) * | 2011-08-18 | 2016-09-01 | 葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之胺基喹唑啉類 |
| MX347765B (es) * | 2011-09-30 | 2017-05-12 | Oncodesign Sa | Inhibidores macrociclicos de la quinasa flt3. |
| PT2760453T (pt) * | 2011-09-30 | 2016-08-02 | Ipsen Pharma Sas | Inibidores macrocíclicos da cinase lrrk2 |
| CA2906262A1 (en) * | 2013-03-15 | 2014-09-18 | Oncodesign S.A. | Macrocyclic salt-inducible kinase inhibitors |
| PL2970333T3 (pl) * | 2013-03-15 | 2017-12-29 | Oncodesign S.A. | Makrocykliczne inhibitory kinazy LRRK2 |
-
2014
- 2014-03-14 WO PCT/EP2014/055139 patent/WO2014140299A1/en not_active Ceased
- 2014-03-14 JP JP2015562211A patent/JP2016510796A/ja not_active Withdrawn
- 2014-03-14 SG SG11201507594YA patent/SG11201507594YA/en unknown
- 2014-03-14 MX MX2015012526A patent/MX2015012526A/es unknown
- 2014-03-14 CN CN201480023821.5A patent/CN105228625A/zh active Pending
- 2014-03-14 EA EA201591773A patent/EA201591773A1/ru unknown
- 2014-03-14 BR BR112015022982A patent/BR112015022982A2/pt not_active IP Right Cessation
- 2014-03-14 US US14/776,889 patent/US20160024114A1/en not_active Abandoned
- 2014-03-14 AU AU2014230111A patent/AU2014230111A1/en not_active Abandoned
- 2014-03-14 KR KR1020157029469A patent/KR20150133765A/ko not_active Withdrawn
- 2014-03-14 HK HK16106342.4A patent/HK1218263A1/zh unknown
- 2014-03-14 CA CA2906257A patent/CA2906257A1/en not_active Abandoned
-
2015
- 2015-09-07 IL IL241250A patent/IL241250A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2014230111A1 (en) | 2015-10-29 |
| CA2906257A1 (en) | 2014-09-18 |
| CN105228625A (zh) | 2016-01-06 |
| JP2016510796A (ja) | 2016-04-11 |
| BR112015022982A2 (pt) | 2017-07-18 |
| KR20150133765A (ko) | 2015-11-30 |
| MX2015012526A (es) | 2016-04-26 |
| IL241250A0 (en) | 2015-11-30 |
| US20160024114A1 (en) | 2016-01-28 |
| SG11201507594YA (en) | 2015-10-29 |
| WO2014140299A1 (en) | 2014-09-18 |
| HK1218263A1 (zh) | 2017-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201591698A1 (ru) | Макроциклические ингибиторы киназы lrrk2 | |
| MX2015012526A (es) | Inhibodores macrociclicos de cinasa rip2. | |
| MX2015012528A (es) | Inhibidores macrociclicos de cinasa inducibles por sal. | |
| EA201690159A1 (ru) | Способы и композиции для лечения рака | |
| MX2019001125A (es) | Inhibidores de cinasa macrociclica. | |
| MX2020010535A (es) | Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide. | |
| MX2016008131A (es) | Compuestos heterociclos biciclicos y sus usos en terapia. | |
| NZ751197A (en) | Compounds and methods of treating infections | |
| EA201591166A1 (ru) | Ингибиторы аутотаксина | |
| IN2015DN01156A (enExample) | ||
| EA201790576A1 (ru) | Спироциклические ингибиторы катепсина с | |
| MX2016006975A (es) | Compuestos, composicion farmaceutica y metodos para su uso en el tratamiento de enfermedades inflamatorias. | |
| BR112015017241A2 (pt) | doadores de nitroxil com índice terapêutico melhorado | |
| TR201904514T4 (tr) | Makrosiklik LRRK2 kinaz inhibitörleri. | |
| EA201491672A1 (ru) | Гетероциклильные соединения как ингибиторы mek | |
| AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
| CL2015000615A1 (es) | Compuestos derivados de 4-amino-quinolinas, inhibidores de rip2 cinasa; composicion farmaceutica que los comprende; uso para el tratamiento de enfermedades tales como enfermedad de crohn, colitis ulcerativa o sindrome de blau. | |
| EA201690039A1 (ru) | Ингибиторы rorc2 и способы их применения | |
| EA201692481A1 (ru) | Комбинация, содержащая глюкокортикоид и edo-s101 | |
| EA201790726A1 (ru) | Фармацевтическая композиция для лечения язвенного колита | |
| EA201792341A1 (ru) | Производные пиразола, пригодные в качестве ингибиторов белка, активирующего 5-липоксигеназу (flap) | |
| EA201791363A1 (ru) | Пиразолопиридинамины в качестве ингибиторов mknk1 и mknk2 | |
| EA201501187A1 (ru) | Новые химические соединения (варианты) и их применение для лечения онкологических заболеваний | |
| BR112017004580A2 (pt) | composto, composição farmacêutica, produto de combinação, uso de um composto ou sal farmaceuticamente aceitável, e, método de tratamento. | |
| EA201790609A1 (ru) | Макроциклические ингибиторы rip2-киназы |